{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:29:37Z","timestamp":1773797377637,"version":"3.50.1"},"reference-count":21,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"3","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: The present study intends to explore the dynamic variations in Irisin, fibroblast growth factor 23 (FGF-23), and N-terminal propeptide of osteocalcin (N-MID) among diabetes mellitus osteoporosis (DOP) patients undergoing treatment with acarbose plus sitagliptin, as well as their ability to predict bone metabolic status and fracture risk. The ultimate objective is to identify potential biomarkers for optimizing DOP therapy. Methods: From January 2023 to March 2024, 124 DOP patients admitted to our hospital were administered acarbose in combination with sitagliptin. For comparison, 119 uncomplicated diabetes mellitus (DM) patients were recruited as controls. Serum levels of Irisin, FGF-23, and N-MID were tested both at baseline and post-treatment. Data on bone mineral density (BMD), bone metabolic markers, and fracture occurrences during follow-up were also collected. Results: Compared with uncomplicated DM individuals, DOP patients exhibited a rise in FGF-23 (P&amp;lt; 0.05) and a decrease in Irisin and N-MID (P&amp;lt; 0.05). Irisin + FGF-23 + N-MID combination demonstrated 87.10% sensitivity and 74.58% specificity in diagnosing DOP (AU C= 0.867). Treatment with acarbose and sitagliptin contributed to reduced FGF-23 in DOP patients, along with increased Irisin and N-MID (P&amp;lt; 0.05). BMD was positively influenced by irisin but negatively affected by FGF-23. Fracture prediction efficacy was markedly enhanced (AU C= 0.822) by combining the three indices, with statistical superiority over single-index analysis (P&amp;lt; 0.05). Conclusions: The combined detection of Irisin, FGF-23, and N-MID enables early detection of DOP while allowing for dynamic assessment of treatment outcomes and fracture risk.<\/jats:p>","DOI":"10.5937\/jomb0-60451","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:06:43Z","timestamp":1756807603000},"page":"529-538","source":"Crossref","is-referenced-by-count":0,"title":["Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis"],"prefix":"10.5937","volume":"45","author":[{"given":"Lilan","family":"Zhou","sequence":"first","affiliation":[{"name":"Affiliated Hospital of JiuJiang University, Department of Endocrinology, Jiujiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghua","family":"Peng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Gannan Medical University, Department of Burn and Wound Repair, Gannan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Subarajan P Arceo-Mendoza RM, Camacho PM. Postmenopausal Osteoporosis: A Review of Latest Guidelines. Endocrinol Metab Clin North Am 2024; 53(4): 497-512;","DOI":"10.1016\/j.ecl.2024.08.008"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Liu C, Lv H, Niu P Tan J, Ma Y Association between diabetic neuropathy and osteoporosis in patients: a systematic review and meta-analysis. Arch Osteoporos 2020; 15(1): 125;","DOI":"10.1007\/s11657-020-00804-6"},{"key":"ref3","unstructured":"Kalra S, Joshi A, Kapoor N. Osteoporosis and diabetes: The dual pandemics. J Pak Med Assoc 2022; 72(8): 1663-4;"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Mao Y, Li K, Zhu B, Long J. Analysis of risk factors and predictive efficacy of senile osteoporosis fracture based on biochemical indicators of bone metabolism. J Med Biochem 2024; 43 (3): 451-9;","DOI":"10.5937\/jomb0-46663"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Chi PJ, Hung SY, Hsiao FT, Liou HH, Tsai JP Serum osteocalcin concentration as an independent biomarker of osteoporosis in patients with chronic kidney disease. Clin Nephrol 2022; 98(1): 1-9;","DOI":"10.5414\/CN110705"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yang J, Zhang Y Liu X , Chen B, Lei L. Effect of type 2 diabetes on biochemical markers of bone metabolism: a meta-analysis. Front Physiol 2024; 15: 1330171;","DOI":"10.3389\/fphys.2024.1330171"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zhao R, Chen Y Wang D, Zhang C, Song H, Ni G. Role of irisin in bone diseases. Front Endocrinol (Lausanne) 2023; 14: 1212892;","DOI":"10.3389\/fendo.2023.1212892"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Portales-Castillo I, Simic P PTH, FGF-23, Klotho and Vitamin D as regulators of calcium and phosphorus: Genetics, epigenetics and beyond. Front Endocrinol (Lausanne) 2022; 13: 992666;","DOI":"10.3389\/fendo.2022.992666"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Guo X , Shen Y Du T He Y Lu J, Yang Q. Elevations of N-Terminal Mid-Fragment of Osteocalcin and Cystatin C Levels are Associated with Disorders of Glycolipid Metabolism and Abnormal Bone Metabolism in Patients with Type 2 Diabetes Mellitus Complicated with Osteoporosis. J Physiol Investig 2024; 67(6): 335-43;","DOI":"10.4103\/ejpi.EJPI-D-24-00042"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Harreiter J, Roden M. Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023). Wien Klin Wochenschr 2023; 135(Suppl 1): 7-17;","DOI":"10.1007\/s00508-022-02122-y"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Arceo-Mendoza RM, Camacho PM. Postmenopausal Osteoporosis: Latest Guidelines. Endocrinol Metab Clin North Am 2021; 50(2): 167-78;","DOI":"10.1016\/j.ecl.2021.03.009"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hu X , Wang Z, Wang W, Cui P Kong C, Chen X , et al. Irisin as an agent for protecting against osteoporosis: A review of the current mechanisms and pathways. J Adv Res 2024; 62: 175-86;","DOI":"10.1016\/j.jare.2023.09.001"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Zerlotin R, Oranger A, Pignataro P Dicarlo M, Maselli F , Mori G, et al. Irisin and Secondary Osteoporosis in Humans. Int J Mol Sci 2022; 23(2);","DOI":"10.3390\/ijms23020690"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Zhang X , Xu J. Fibroblast growth factor 23-mediated regulation of osteoporosis: Assessed via Mendelian randomization and in vitro study. J Cell Mol Med 2024; 28(14): e18551;","DOI":"10.1111\/jcmm.18551"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Hannemann A, Nauck M, Volzke H, Weidner H, Platzbecker U, Hofbauer LC, et al. Interactions of Anemia, FGF-23, and Bone in Healthy Adults-Results From the Study of Health in Pomerania (SHIP). J Clin Endocrinol Metab 2021; 106(1): e288-e99;","DOI":"10.1210\/clinem\/dgaa716"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Guo Y, Ge X , Wang W, Wang R, Chen Q, Wang H. Epimedium applied in the clinical treatment of osteoporosis patients with periodontitis. Medicine (Baltimore) 2024; 103(50): e40837;","DOI":"10.1097\/MD.0000000000040837"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Ji X , Hu X , Xu T, Yang W. Roles of myokines in osteoporosis under physiological and diabetic conditions. Front Endocrinol (Lausanne) 2025; 16: 1600218;","DOI":"10.3389\/fendo.2025.1600218"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Li X , McPherson M, Hager M, Lee M, Chang P Miller RA. Four anti-aging drugs and calorie-restricted diet produce parallel effects in fat, brain, muscle, macrophages, and plasma of young mice. Geroscience 2023; 45(4): 2495-510;","DOI":"10.1007\/s11357-023-00770-0"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Elbarbary NS, Ismail EA, El-Hamamsy MH, Ibrahim MZ, Elkholy AA. The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial. Diabetologia 2024; 67(12): 2637-49;","DOI":"10.1007\/s00125-024-06265-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Medina Neri AK, Silva RP Meneses GC, Costa Martins AM, Portela Lima AO, Callou Filho CR, et al. Association between endothelial biomarkers and lipid and glycemic levels: a cross-sectional study with diabetic patients. Biomark Med 2023; 17(22): 935-46;","DOI":"10.2217\/bmm-2023-0174"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Xu JX, Fang K, Gao XR, Liu S, Ge JF Resveratrol Protects SH-SY5Y Cells Against Oleic Acid-Induced Glucolipid Metabolic Dysfunction and Cell Injuries Via the Wnt\/beta-Catenin Signalling Pathway. Neurochem Res 2021; 46(11): 2936-47;","DOI":"10.1007\/s11064-021-03398-8"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Varijacije i implikacije Irisina, FGF-23 i N-MID osteokalcina kod pacijenata sa dijabeti\u010dkom osteoporozom koji se podvrgavaju terapiji akarbozom plus sitagliptin - prospektivna kohortna analiza"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/60451\/28636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582603529Z.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T21:17:16Z","timestamp":1773782236000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582603529Z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-60451","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}